# Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

> **NCT02248259** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 409306
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT02248259
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2015-01-07
- **Final completion:** 2015-01-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248259, "Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02248259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*